Skip to main content
. 2021 Apr 6;22:99. doi: 10.1186/s12931-021-01698-9

Fig.4.

Fig.4

In silico and in vitro effect of AV on SARS-CoV2 targets (a, b) Molecular docking interaction of AV’s a Luteolin-6-C-glucoside-8-C-arabinoside with SARS-CoV2 3CLpro, and b Luteolin-6,8-di-C-glucoside with SARS-CoV2 NSP14 protein. c AV treatment inhibits the viral replication in cellular model of SARS-CoV2. Graph showing increase in Viral Reduction (%) to an increase in Ct Values. Y-Axis (left): Viral Reduction (%); Y’-Axis (Right): Ct Values; X-Axis: Concentrations of AV (µg/mL)